Carlos López López

10PUBLICATIONS
92CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersEpidemiological methodsGeospatial information systems and geospatial data modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Apr 21, 2026
Amivantamab Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study.

|Feb 20, 2026
Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107).

Rocio Garcia-Carbonero, Marta Benavent, Paula Jimenez-Fonseca

|Nov 19, 2025
Clinical and treatment patterns of advanced and radioiodine-refractory differentiated thyroid cancer. ERUDIT study.

Carlos López López, Marcel Sambo, Lorenzo Orcajo-Rincon

|Sep 12, 2025
Cabozantinib plus Atezolizumab in Advanced, Progressive Endocrine Malignancies: A Multicohort, Basket, Phase II Trial (CABATEN/GETNE-T1914).

Jaume Capdevila, Jorge Hernando, Javier Molina-Cerrillo

|Feb 24, 2025
Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry.

Alberto Carmona-Bayonas, Cristina Álvarez-Escolá, Inmaculada Ballester Navarro

|Jun 24, 2024
SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023).

Carlos López López, Mariona Calvo, Juan Carlos Cámara

Pageof 2

Frequent Collaborators

3 joint publications

Paula Jimenez-Fonseca

3 joint publications

Rocio Garcia-Carbonero

3 joint publications

Jorge Hernando Cubero

3 joint publications

Teresa Alonso-Gordoa